论文部分内容阅读
[目的]研究金葡液治疗癌性胸水的临床疗效。[方法]45例癌性胸水病人被随机分为3组 ,均行胸腔穿刺术,尽量抽尽胸水。单用金葡液组(单金组) :胸腔内注入金葡液2000U。单用顺铂组(单化组) :胸腔内注入顺铂40mg～60mg。金葡液联合顺铂组(联合组) :胸腔内注入金葡液2000U加顺铂40mg～60mg。每周2次 ,一般2～4次。[结果]单金组、单化组、联合组治疗癌性胸水的有效率(CR +PR)分别为53 3 %、46 7%、86 7% ;单金组与单化组比较无明显差异(P>0 05) ,联合组分别与单金组和单化组比较均差异显著(P<0 05)。在活动状况提高方面 ,单金组稍优于单化组(P>0 05) ,联合组明显优于单化组(P<0 05)。联合组的白细胞下降及恶心呕吐的发生率明显低于单化组(P<0 05)。[结论]金葡液是治疗癌性胸水的有效药物 ,与顺铂联合可增效减毒 ,提高生存质量。
[Objective] To study the clinical efficacy of Jin Pu solution in the treatment of cancerous pleural effusion. [Methods] 45 patients with cancerous pleural effusion were randomly divided into 3 groups. Thoracentesis was performed and pleural effusion was exhausted. Single use of gold solution group (single gold group): intrapleural injection of gold 2000U. Cisplatin alone (single group): Intrapleural cisplatin 40 mg to 60 mg was injected into the chest. Golden Pulp Solution Combined with Cisplatin (combined group): Intrapleural injection of 2000U of Golden Pulp and 40mg to 60mg of cisplatin. 2 times a week, usually 2 to 4 times. [Results] The effective rates (CR + PR) of cancerous pleural effusions in the single gold group, the single group and the combined group were 53 3%, 46 7%, and 86 7%, respectively; there was no significant difference between the single gold group and the single group. (P>0 05), the combination group was significantly different from the single gold group and the single group (P < 0 05). In the improvement of activity status, the single gold group was slightly better than the single group (P>0.05), and the combined group was significantly better than the single group (P<0 05). The incidence of white blood cell decline and nausea and vomiting in the combined group was significantly lower than that in the single group (P<0.05). [Conclusion] Golden Pulp is an effective drug for the treatment of cancerous pleural effusion, and it can be combined with cisplatin to enhance efficacy and attenuation and improve the quality of life.